Genetic overlap between polycystic ovary syndrome and bipolar disorder: The endophenotype hypothesis

Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Center for Neuroscience in Women's Health, 401 Quarry Road, Stanford, CA 94305, United States. bowenj@stanford.
Medical Hypotheses (Impact Factor: 1.07). 07/2009; 73(6):996-1004. DOI: 10.1016/j.mehy.2008.12.056
Source: PubMed


Polycystic Ovary Syndrome (PCOS) is a polygenic disorder caused by the interaction of susceptible genomic polymorphisms with environmental factors. PCOS, characterized by hyperandrogenism and menstrual abnormalities, has a higher prevalence in women with Bipolar Disorder (BD). Theories explaining this high prevalence have included the effect of PCOS itself or the effect of drugs such as Valproate, which may cause PCOS either directly or indirectly. Incidentally, metabolic abnormalities are observed in both bipolar and PCOS patients. Endophenotypes such as insulin resistance, obesity, and hyperglycemia are common among BD and PCOS patients, suggesting some degree of pathophysiological overlap. Since both BD and PCOS are complex polygenetic diseases, the endophenotype overlap may be the result of common genetic markers. This paper postulates that shared clinical endophenotypes between PCOS and BD indicate common pathophysiological platforms and will review these for the potential of genetic overlap between the two disorders.

Download full-text


Available from: Bowen Jiang, Jan 27, 2014
  • Source
    • "Mood stabilizers such as lithium and anticonvulsants also carry the risk of significant weight gain, drowsiness, and decreased cognition, as well as the development of tremors. Many of these medications carry risks to fetuses, leading the JAACAP practice parameter to recommend that clinicians perform adjunctive pregnancy tests and specifically warn female patients and their families about concerns regarding the anticonvulsant valproate and polycystic ovary disease [57,67,68]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This commentary grows out of an interdisciplinary workshop focused on controversies surrounding the diagnosis and treatment of bipolar disorder (BP) in children. Although debate about the occurrence and frequency of BP in children is more than 50 years old, it increased in the mid 1990s when researchers adapted the DSM account of bipolar symptoms to diagnose children. We offer a brief history of the debate from the mid 90s through the present, ending with current efforts to distinguish between a small number of children whose behaviors closely fit DSM criteria for BP, and a significantly larger number of children who have been receiving a BP diagnosis but whose behaviors do not closely fit those criteria. We agree with one emerging approach, which gives part or all of that larger number of children a new diagnosis called Severe Mood Dysregulation or Temper Dysregulation Disorder with Dysphoria. Three major concerns arose about interpreting the DSM criteria more loosely in children than in adults. If clinicians offer a treatment for disorder A, but the patient has disorder B, treatment may be compromised. Because DSM's diagnostic labels are meant to facilitate research, when they are applied inconsistently, such research is compromised. And because BP has a strong genetic component, the label can distract attention from the family or social context. Once a BP diagnosis is made, concerns remain regarding the primary, pharmacological mode of treatment: data supporting the efficacy of the often complex regimens are weak and side effects can be significant. However, more than is widely appreciated, data do support the efficacy of the psychosocial treatments that should accompany pharmacotherapy. Physicians, educators, and families should adopt a multimodal approach, which focuses as much on the child's context as on her body. If physicians are to fulfill their ethical obligation to facilitate truly informed consent, they must be forthcoming with families about the relevant uncertainties and complexities.
    Child and Adolescent Psychiatry and Mental Health 03/2010; 4(1):9. DOI:10.1186/1753-2000-4-9
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The insulin receptor substrate gene-1 (IRS-1) polymorphisms have been incriminated in insulin resistance; a frequent finding in polycystic ovary syndrome (PCOS). The commonest polymorphism associated with insulin resistance is gly972arg. Another polymorphism is the ala512 pro. This study aimed at elucidating the association of the gly972arg and the ala512pro polymorphisms of the IRS-1 gene with PCOS in Egyptian females. We employed a case–control study. The two polymorphisms were analyzed in 62 PCOS Egyptian female patients and 43 age-matched controls using a PCR-RFLP strategy. Fasting insulin, plasma glucose, and testosterone were analyzed by routine analytical methods and calculation of the homeostasis model assessment (HOMA) and the quantitative sensitivity check index (QUICK I) were done based on the results of the fasting insulin and glucose. It was found that 6.5% of the PCOS cases showed the Gly972Arg genotype. The Gly972Arg in IRS-1 polymorphism was not associated with PCOS (p = 0.556). A positive association was found between the gly972arg and the HOMA quartiles (p = 0.01). PCOS patients with the 972gly/arg genotype had higher glucose (p = 0.040), insulin (0.000), HOMA (0.000), and lower QUICK I (0.023) than PCOS with wild 972arg/arg genotype. Patients of PCOS with the 972gly/arg genotype were more insulin resistant than other patients with the wild genotype. Neither the patients nor the controls showed the mutant ala512pro genotype. Screening for gly972arg genotype can be based on the HOMA quartile ranking. The ala512pro genotype was not found in studied Egyptian women.
    Comparative Clinical Pathology 12/2011; 21(6). DOI:10.1007/s00580-011-1350-0 · 0.37 Impact Factor

  • 09/2011; 13(5). DOI:10.4088/PCC.11l01164
Show more